OPRK1
Kappa-type opioid receptor
As of the edition of 20 October 2026, OPRK1 (kappa-type opioid receptor, UniProt P41145) has 29 drugs tested at it and 59 companies on the list, 6 on route A and 16 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41145
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 41
- Disease areas
- Mental health; Chemically induced; Nervous system; Skin and connective tissue; Immune system; Bones, joints and muscles; Urinary and reproductive; Infections
- Registered trials of its drugs
- 1,128
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 16 |
| Active | 3 |
| Went quiet | 4 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 29 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Buprenorphine | Marketed | Phase 4 | Ends 2028 |
| Naltrexone | Marketed | Phase 4 | none listed |
| Naloxone | Marketed | Phase 4 | none listed |
| Hydrocodone | Marketed | Phase 4 | none listed |
| Nalbuphine | Marketed | Phase 4 | none listed |
| Codeine | Marketed | Phase 4 | none listed |
| Nalmefene | Marketed | Phase 4 | none listed |
| Difelikefalin | Marketed | Phase 3 | Ends 2032 |
| Oxymorphone | Marketed | Phase 4 | Ends 2029 |
| Aticaprant | Active | Phase 3 | none listed |
| Cebranopadol | Stopped | Phase 3 | none listed |
| HSK21542 | Active | Phase 4 | none listed |
12 of 29 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 16 |
| Engaged | 18 |
| Undetermined | 19 |
| Total on the list | 59 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Roche | Route B |
| Neumora Therapeutics | Route A |
The other 56 companies at OPRK1
In the product59 companies in all; 56 are not named here, and no score is.
See the 59 companies at OPRK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.